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Abstract 
The accuracy of the signs and tests that clinicians use to diagnose ventilator‑associated pneumonia (VAP) and initiate 
antibiotic treatment has not been well characterized. We sought to characterize and compare the accuracy of physical 
examination, chest radiography, endotracheal aspirate (ETA), bronchoscopic sampling cultures (protected specimen 
brush [PSB] and bronchoalveolar lavage [BAL]), and CPIS > 6 to diagnose VAP. We searched six databases from incep‑
tion through September 2019 and selected English‑language studies investigating accuracy of any of the above tests 
for VAP diagnosis. Reference standard was histopathological analysis. Two reviewers independently extracted data 
and assessed study quality. We included 25 studies (1639 patients). The pooled sensitivity and specificity of physical 
examination findings for VAP were poor: fever (66.4% [95% confidence interval [CI]: 40.7–85.0], 53.9% [95% CI 34.5–
72.2]) and purulent secretions (77.0% [95% CI 64.7–85.9], 39.0% [95% CI 25.8–54.0]). Any infiltrate on chest radiography 
had a sensitivity of 88.9% (95% CI 73.9–95.8) and specificity of 26.1% (95% CI 15.1–41.4). ETA had a sensitivity of 75.7% 
(95% CI 51.5–90.1) and specificity of 67.9% (95% CI 40.5–86.8). Among bronchoscopic sampling methods, PSB had a 
sensitivity of 61.4% [95% CI 43.7–76.5] and specificity of 76.5% [95% CI 64.2–85.6]; while BAL had a sensitivity of 71.1% 
[95% CI 49.9–85.9] and specificity of 79.6% [95% CI 66.2–85.9]. CPIS > 6 had a sensitivity of 73.8% (95% CI 50.6–88.5) 
and specificity of 66.4% (95% CI 43.9–83.3). Classic clinical indicators had poor accuracy for diagnosis of VAP. Reliance 
upon these indicators in isolation may result in misdiagnosis and potentially unnecessary antimicrobial use.
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Introduction
Ventilator-associated pneumonia (VAP) is the most com-
mon and fatal nosocomial infection in Intensive Care 
Units (ICU) [1, 2]. VAP is associated with prolonged 
duration of mechanical ventilation and ICU length of 
stay, increased hospital costs, and possibly an increased 
risk of dying [3–6]. VAP is also a major driver of antibi-
otic use in ICU patients [7].
Early identification of VAP is critical because delayed 
administration of antimicrobial therapy has been asso-
ciated with increased mortality [8–10]. However, the 
importance of rapid antibiotic administration must be 
balanced against the risks of unnecessary antibiotics, 
including antibiotic resistance and superinfections [11], 
particularly in the ICU [12]. Finding the right balance is 
challenging because VAP is difficult to diagnose. As there 
is no practical reference standard for VAP, perceived VAP 
rates and outcomes vary widely depending on the defini-
tion applied [13], and up to two-thirds of patients treated 
for VAP may not actually have VAP [14, 15]. Improved 
methods to diagnose VAP and inform the initiation of 
empiric antibiotics are urgently needed.
Clinicians typically rely upon clinical, radiographic, 
and laboratory indicators to diagnose VAP and initiate 
empiric antibiotics. These include fever, purulent secre-
tions, hypoxemia, new or progressive chest radiographic 
infiltrate, elevated white blood cell count, and positive 
cultures of endotracheal aspirates (ETA) or broncho-
scopic sampling techniques (bronchoalveolar lavage 
[BAL] and protected specimen brush [PSB]). Some of 
these have been combined into clinical models, the 
most popular of which is the Clinical Pulmonary Infec-
tion Score (CPIS) [16]. However, despite widespread use 
of these signs and tests, their accuracy to diagnose VAP 
is poorly characterized [1, 17]. We conducted a system-
atic review and meta-analysis to evaluate diagnostic per-
formance (including sensitivity and specificity) of these 
signs and tests, compared with either histopathology of 
lung tissue, or quantitative BAL cultures as reference 
standards. We hypothesized that these individual tests, in 
isolation, had poor diagnostic accuracy for VAP.
Methods
We structured this systematic review according to 
PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines for Diagnos-
tic Test Accuracy [18, 19], the Cochrane Handbook for 
Diagnostic Test Accuracy [20], and existing guidelines for 
reviews of diagnostic accuracy [21], as performed pre-
viously [22, 23]. We registered the study protocol with 
PROSPERO (CRD42019124907).
Search strategy
We searched six databases (MEDLINE, PubMed, 
EMBASE, Scopus, Web of Science, and the Cochrane 
Database of Systematic Reviews) from inception until 
September 1, 2019. An experienced health sciences 
librarian assisted in the development of the search strat-
egy. The search was conducted using the terms “venti-
lator-associated pneumonia” and “ventilator-acquired 
pneumonia” (Supplemental Figure  1). We used the Sci-
ence Citation Index to retrieve reports citing the relevant 
articles identified from our search. We conducted further 
surveillance searches using the ‘Related Articles” feature 
of PubMed [24].
Study selection
We included all English-language articles describing ret-
rospective and prospective observational studies and 
randomized controlled trials (RCTs). We included stud-
ies meeting the following criteria: 1) ≥ 90% adult patients 
(≥ 16  years); 2) conducted in the ICU; 3) included 
patients with ≥ 48  h of invasive mechanical ventilation; 
and 4) evaluated one or more of the following char-
acteristics: fever (defined as body temperature ≥ 38 
degrees Celsius), purulent secretions, leukocytosis (any 
threshold), chest radiography, gram stain, and/or cul-
ture from ETA (≥ 105 colony-forming units [CFU]/mL), 
PSB (≥ 103  CFU/mL), BAL (≥ 104  CFU/mL), or CPIS 
for diagnosis of VAP. For our primary analysis, we used 
a reference standard of histopathology (obtained from 
lung tissue biopsy) for definitive diagnosis of VAP. How-
ever, because histopathology may not always be easily 
obtained and because this reference standard may limit 
generalizability of results, we performed a secondary 
analysis using BAL of the lung with ≥ 104  CFU/mL of a 
pathogen known to cause VAP as the reference standard.
We excluded case reports, case series, animal stud-
ies, and pediatric studies. For all included studies, we 
extracted a 2 × 2 table of true positive, false negative, true 
negative, and false positive counts. We contacted authors 
for further information when these values could not be 
obtained from study reports. If the corresponding author 
did not respond after three attempts, the study was 
excluded.
Take home message 
In this meta‑analysis, we found that physical examination findings 
(fever, purulent secretions), chest radiography, endotracheal aspirate 
cultures, bronchoscopic cultures, and Clinical Pulmonary Infection 
Score (CPIS) have poor accuracy for diagnosing ventilator‑associated 
pneumonia. These findings have important implications for patient 
management, antibiotic stewardship, and quality measurement.
We screened studies using Covidence (Melbourne, 
Australia). Two reviewers (SMF and A. Tran) indepen-
dently screened the titles and abstracts of all studies, in 
order to identify potentially eligible studies. The same 
two reviewers then independently assessed full texts of 
these potentially eligible studies. Disagreements were 
resolved by consensus.
Data extraction
One investigator (SMF) collected the following variables 
from included articles using a pre-designed data extrac-
tion sheet (Supplemental Table 1): Author name, year of 
publication, study design, eligibility criteria, and number 
of patients. Two investigators (SMF and A. Tran) inde-
pendently extracted the true positive, false positive, false 
negative, and true negative counts for all included arti-
cles. Disagreements were resolved through consensus. A 
third investigator (WC) verified all extracted data.
Quality assessment
Two reviewers (SMF and A. Tran) independently 
assessed risk-of-bias of included studies, using the Qual-
ity Assessment of Diagnostic Accuracy Studies (QUA-
DAS-2) tool [25]. QUADAS-2 assesses four potential 
areas for bias and applicability of the research question: 
(1) Patient selection; (2) Index test: potential risk-of-bias 
noted if the index test results were interpreted without 
explicit blinding to gold-standard; (3) Reference stand-
ard: potential risk-of-bias noted if the reference stand-
ard could misclassify the target condition; and (4) Flow 
and timing: potential risk-of-bias noted if not all patients 
had the diagnostic test applied using the same criteria, 
if the diagnostic test was measured at an inappropriate 
time interval prior to the definitive VAP reference stand-
ard, or if patients were inappropriately excluded. Studies 
with potential risk-of-bias in any of these domains were 
judged as high risk-of-bias overall. We performed two 
separate risk-of-bias assessments, one for each reference 
standard.
Evidence synthesis
We presented individual study results graphically by plot-
ting sensitivity and specificity estimates on one-dimen-
sional forest plots(ordered by sensitivity) as well as on the 
Receiver Operating Characteristics (ROC) space, to visu-
ally assess for heterogeneity. To pool the bivariate results, 
we applied the Hierarchical Summary ROC (HSROC) 
model [26], which appropriately incorporates both 
within-study and between-study variability by defining 
separate models for each type of variability. The within-
study variation is described using a binomial distribution 
for the number of positive tests as a function of patients’ 
true mortality status, while the between-study variation 
allows both the “positivity” and “accuracy” parameters 
to vary between studies. We obtained summary point 
estimates of the pairs of sensitivity and specificity, posi-
tive and negative predictive values, as well as diagnostic 
odds ratios and likelihood ratios, along with correspond-
ing 95% confidence intervals (CI). Summary estimates 
of test accuracy were plotted in the ROC space together 
with the summary ROC curve. We conducted all analyses 
using the MetaDAS (version 1.3) [27] macro in SAS (SAS 
Institute), as recommended by the Cochrane Handbook 
for Systematic Review of Diagnostic Test Accuracy [20]. 
Univariate tests for heterogeneity in sensitivity and speci-
ficity are not recommended by the Cochrane Handbook 
for Systematic Reviews of Diagnostic Test Accuracy, as 
they did not account for heterogeneity explained by phe-
nomena referred to  as  the "positive threshold effects" 
[20]. Instead, it is preferable to demonstrate heterogene-
ity graphically through the scatterplot and the confidence 
region of the bivariate summary point within the  ROC 
plane and the descriptive  forest plots. For our primary 
analysis using histopathology as the reference standard, 
we conducted a predefined sensitivity analysis excluding 
studies that did not also use tissue culture for the diagno-
sis of VAP.
We assessed the overall certainty in pooled diagnostic 
effect estimates using the Grading of Recommendations, 
Assessments, Development and Evaluation (GRADE) 
approach [28, 29]. The overall confidence in effect esti-
mates was categorized as high, moderate, low, or very 
low. We created a GRADE evidence profile for each 




We identified 1,464 potentially relevant citations (Fig. 1). 
Following duplicate removal, 1042 studies were screened, 
and 38 underwent full-text review. We included 25 stud-
ies in the meta-analysis [30–54]. Of these, 15 used his-
topathology from lung biopsy as reference standard [30, 
31, 33, 36, 37, 39, 40, 43, 45, 46, 49, 51–54], while 10 used 
positive BAL culture as reference standard [32, 34, 35, 38, 
41, 42, 44, 47, 48, 50]. Unpublished data from one study 
were obtained from the principal investigators (A. Tor-
res, OTR) [38].
Study characteristics
Study characteristics are displayed in Table  1, with 
detailed review in Supplemental Table  2. Of the stud-
ies included, 17 (68.2% of patients) were performed in 
Europe, 6 (21.3% of patients) in North America, 1 (8.5% 
of patients) in Asia, and 1 (2.1% of patients) in South 
America. 21 studies (61.8% of patients) were prospective 
cohort studies, while the remaining 4 (38.2% of patients) 
were retrospective cohort studies.
Quality assessment
Quality assessments are summarized in Supplemen-
tal Figures  2–3. Three studies were considered to have 
high risk-of-bias: One because it included only patients 
diagnosed with acute respiratory distress syndrome 
(ARDS) [30], and two because patients who underwent 
bronchoscopy (at the judgment of the treating clinician) 
were retrospectively included, leading to potential bias 
in patient selection [35, 47]. Four retrospective studies 
Fig. 1 Flow chart summarizing evidence search and study selection
were noted to have unclear risk-of-bias [30, 45, 51, 54], 
because it was not explicitly stated whether diagnos-
tic adjudicators (i.e., those evaluating histology) were 
blinded to the test characteristics of the individual 
patients.
Results of synthesis
Primary analysis—reference standard of histology
Pooled sensitivity and specificity of clinical signs, relative 
to histopathology, are shown in Table  2. Corresponding 
forest plots and HSROC curves are shown in Supplemen-
tal Figures 4–11. GRADE evidence profiles are depicted 
in Supplemental Tables 3–10.
Table 1 Characteristics of the 25 included studies
Description Overall (25 studies, n = 1781) Histology reference standard (15 studies, 
n = 747)
Bronchoalveolar lavage 
reference standard (10 studies, 
n = 1034)





Europe 17 (68) 1,214 (68.2) 11 (73.3) 578 (77.4) 6 (60) 636 (61.5)
North America 6 (24) 379 (21.3) 3 (20) 132 (17.7) 3 (30) 247 (23.9)
Asia 1 (4) 151 (8.5) 0 (0) 0 (0) 1 (10) 151 (14.6)
South America 1 (4) 37 (2.1) 1 (6.7) 37 (5) 0 (0) 0 (0)
Year of publication
1980–1989 3 (12) 109 (6.1) 3 (20) 109 (14.6) 0 (0) 0 (0)
1990–1999 10 (40) 334 (18.8) 9 (60) 274 (36.7) 1 (10) 60 (5.8)
2000–2009 6 (24) 437 (24.5) 3 (20) 111 (14.9) 3 (30) 326 (31.5)
2010–2018 6 (24) 901 (50.6) 1 (6.7) 253 (33.9) 5 (50) 648 (62.7)
Study design
Prospective Cohort 21 (84) 1,100 (61.8) 14 (93.3) 494 (66.1) 7 (70) 606 (58.6)
Retrospective cohort 4 (16) 681 (38.2) 1 (6.7) 253 (33.9) 3 (30) 428 (41.4)
Table 2 Summary estimates of the performance of physical examination, chest radiography, laboratory values, and CPIS 
for the diagnosis of ventilator-associated pneumonia, relative to reference standard of histopathology from lung biopsy



















Fever 5 (142) 66.4 (40.7–85) 53.9 (34.5–72.2) 2.31 (0.98–5.43) 1.44 (1.01–2.05) 0.62 (0.36–1.09) Low
Purulent secretions 4 (336) 77 (64.7–85.9) 39 (25.8–54) 2.13 (1.34–3.41) 1.26 (1.06–1.5) 0.59 (0.42–0.83) Moderate
Infiltrate on chest 
radiography
7 (238) 88.9 (73.9–95.8) 26.1 (15.1–41.4) 2.83 (1.18–6.82) 1.2 (1.03–1.4) 0.42 (0.2–0.92) Low




3 (75) 75.7 (51.5–90.1) 67.9 (40.5–86.8) 6.59 (2.17–20.04) 2.36 (1.19–4.66) 0.36 (0.18–0.73) Very Low
Protected specimen 
brush (> 103 CFU/mL)
7 (201) 61.4 (43.7–76.5) 76.5 (64.2–85.6) 5.19 (2.31–11.65) 2.62 (1.63–4.19) 0.5 (0.33–0.77) Low
Bronchoalveolar lavage 
(> 104 CFU/mL)
10 (307) 71.1 (49.9–85.9) 79.6 (66.2–88.6) 9.57 (4.04–22.71) 3.48 (2.13–5.7) 0.36 (0.2–0.66) Low
CPIS > 6 4 (343) 73.8 (50.6–88.5) 66.4 (43.9–83.3) 5.56 (1.30–23.84) 2.2 (1.09–4.43) 0.4 (0.17–0.92) Low
Among physical examination features, the presence 
of fever had a pooled sensitivity of 66.4% (95% CI 40.7–
85.0, low certainty), and specificity of 53.9% (95% CI 
34.5–72.2, low certainty). Purulent secretions had a sen-
sitivity of 77.0% (95% CI 64.7–85.9, moderate certainty), 
and specificity of 39.0% (95% CI 25.8–54.0, moderate 
certainty). Presence of infiltrate on plain chest radiog-
raphy had a sensitivity of 88.9% (95% CI 73.9–95.8, low 
certainty) and specificity of 26.1% (95% CI 15.1–41.4, low 
certainty). Leukocytosis was only evaluated in three stud-
ies of which two defined leukocytosis as a white blood 
cell count ≥ 10 × 109/L [31, 37], while one study defined it 
as a count ≥ 12 × 109/L [40]. Pooled sensitivity for leuko-
cytosis was 64.2% (95% CI 46.9–78.4, low certainty) and 
specificity 59.2% (95% CI 45.0–72.0, low certainty).
We evaluated pathogen growth from three different 
sampling techniques. Positive ETA had a sensitivity of 
75.7% (95% CI 51.5–90.1, very low certainty) and speci-
ficity of 67.9% (95% CI 40.5–86.8, very low certainty). 
PSB from bronchoscopy had a sensitivity of 61.4% (95% 
CI 43.7–76.5, low certainty) and specificity of 76.5% (95% 
CI 64.2–85.6, low certainty), while BAL from bronchos-
copy had a sensitivity of 71.1% (95% CI 49.9–85.9, low 
certainty) and specificity of 79.6% (95% CI 66.2–88.6, low 
certainty). There were insufficient studies available for 
meta-analysis of gram stain accuracy.
Finally, CPIS > 6 had a pooled sensitivity of 73.8% (95% 
CI 50.6–88.5, low certainty) and specificity of 66.4% (95% 
CI 43.9–83.3, low certainty).
Although several of the included studies examined 
combinations of signs or tests (Table 3), none of the spe-
cific combinations were evaluated in multiple studies, 
thus precluding meta-analysis. Three studies [40, 51, 52] 
evaluated combinations of clinical signs with concurrent 
infiltrate on chest radiography. The presence of infiltrate 
coupled with ≥ 1 of (fever, purulent secretions, or leu-
kocytosis) had a sensitivity of 65–85% and specificity of 
33–36%, whereas an infiltrate and all 3 signs had a sensi-
tivity of 16–23% and specificity of 91–92%.
Sensitivity analyses—excluding studies with histology alone 
as reference standard
We repeated our primary analysis after excluding studies 
that used histopathology alone (without tissue culture) as 
the reference standard. Pooled estimates and conclusions 
were consistent with the primary analysis (Supplemental 
Table 11 and Supplemental Figures 12–15).
Secondary analysis—reference standard of Bronchoalveolar 
lavage
The results of our secondary analysis of studies using 
BAL ≥ 104 CFU/mL of a known pathogenic VAP organ-
ism as reference standard are shown in Table  4. Corre-
sponding forest plots and HSROC curves are shown in 
Supplemental Tables  16–18. GRADE evidence profiles 
are depicted in Supplemental Tables 11–13.
Three features had a suitable number of studies for 
meta-analysis using this reference standard. Presence of 
purulent secretions had a sensitivity of 87.9% (95% CI 
68.3–96.1, low certainty) and specificity of 38.8% (95% 
CI 20.4–61.0, low certainty). Presence of an infiltrate 
on chest radiography had a sensitivity of 85.2% (95% CI 
52.9–96.7, low certainty) and specificity of 18.0% (95% 
CI 4.7–49.7, low certainty). CPIS > 6 had a sensitivity of 
Table 3 Summary estimates of the performance of combinations of clinical findings from individual studies
CI = confidence interval. *2 × 2 table not provided in paper
Sensitivity, %  
(95% CI)
Specificity, %  
(95% CI)
Positive likeli-
hood ratio  
(95% CI)
Negative likeli-
hood ratio  
(95% CI)
Tejerina et al. [51] (142 with VAP, 111 without VAP)
 Chest radiography infiltrate + any 1 of: leukocytosis, fever, 
purulent secretions
64.8 (56.6–72.2) 36 (27.7–45.3) 1.01 (0.84–1.22) 0.98 (0.7–1.36)
 Chest radiography infiltrate + all 3 of: leukocytosis, fever, 
purulent secretions
15.5 (10.5–22.3) 91 (84.2–95) 1.72 (0.85–3.48) 0.93 (0.85–1.02)
Fabregas et al. [40] (13 with VAP, 12 without VAP)
 Chest radiography infiltrate + any 1 of: leukocytosis, fever, 
purulent secretions
84.6 (57.8–95.7) 33.3 (13.8–60.9) 1.27 (0.8–2.02) 0.46 (0.1–2.08)
Chest radiography infiltrate + any 2 of: leukocytosis, fever, 
purulent secretions
69.2 (42.4–87.3) 75 (46.8–91.1) 2.77 (0.97–7.87) 0.41 (0.17–0.99)
 Chest radiography infiltrate + all 3 of: leukocytosis, fever, 
purulent secretions
23.1 (8.2–50.3) 91.7 (64.6–98.5) 2.77 (0.33–23.14) 0.84 (0.6–1.18)
Torres et al. [52] (18 with VAP, 12 without VAP)
 Purulent secretions and either: A) leukocytosis; OR B) chest 
radiography infiltrate*
70 45
75.4% (95% CI 38.5–93.7, low certainty) and specificity of 
68.3% (95% CI 42.9–86.1, low certainty).
Discussion
We performed a systematic review and meta-analyses to 
investigate the accuracy of physical examination findings, 
leukocytosis, chest radiography, ETA (≥ 105  CFU/mL), 
bronchoscopic sample cultures [PSB (≥ 103  CFU/mL) 
and BAL (≥ 104  CFU/mL)], and CPIS (> 6) for diagno-
sis of VAP in critically ill adults. When evaluating these 
signs against the reference standard of lung histopathol-
ogy, we found that none were very accurate. The presence 
of infiltrate on plain chest radiography had the highest 
sensitivity (88.9%); however, all signs had poor specific-
ity. Results were similar when using BAL as the reference 
standard: purulent secretions and infiltrate on chest radi-
ography had modest sensitivity (87.9% and 85.2%), but all 
signs had poor specificity. CPIS was inaccurate, regard-
less of the reference standard used. Our study suggests 
that the individual signs and tests clinicians routinely use 
to diagnose VAP and inform initiation of antibiotics in 
the ICU are neither sensitive nor specific.
Some clinicians perceive that BAL overcomes the lim-
ited accuracy of clinical signs, but our results suggest that 
quantitative BAL cultures are also subject to high rates of 
both false positives and false negatives [49]. Several stud-
ies have used BAL as a reference standard in the evalu-
ation of other VAP diagnostic tools, such as biomarkers 
[42, 55]. The limited accuracy of BAL to diagnose VAP 
should be considered when interpreting these stud-
ies.  The more reliable reference standard for VAP diag-
nosis is histopathology from lung biopsy [39], but this 
is impractical for routine diagnosis, may be influenced 
by the area of the lung that is biopsied, and is itself sub-
ject to disagreement between pathologists [1, 56]. The 
accuracy of various clinical signs has been evaluated in 
two previous systematic reviews [1, 17]; however, meta-
analysis, summarizing pooled sensitivity and specificity, 
was not performed. As such, this study provides novel 
data highlighting the poor accuracy of the signs and tests 
commonly used to diagnose VAP in mechanically venti-
lated patients.
Our analyses suggest that none of the indicators we 
evaluated have sufficient sensitivity to safely rule out 
VAP in susceptible patients. Our findings also highlight 
the need to be mindful of the possibility of VAP, even 
in patients without classic clinical signs. Conversely, 
none of the evaluated clinical indicators had sufficient 
specificity to rule in a diagnosis of VAP. Bayesian analy-
sis demonstrates that the individual signs we evaluated 
do little to alter provider pre-test probability (Supple-
mental Tables  14–15). For example, in a patient with a 
50% pre-test probability of VAP, absence of infiltrate on 
chest x-ray only reduces the post-test probability to 30%, 
while presence of infiltrate only increases it to 55%. We 
also sought to evaluate the accuracy of gram stain, but 
there were not enough studies to meta-analyze this for 
either reference standard.
It remains unclear if combinations of particular signs 
increase diagnostic accuracy. The CPIS score combines a 
number of patient features, but our analysis found it still 
has poor sensitivity and specificity. These findings there-
fore suggest that neither individual signs nor the CPIS is 
reliable indicator of VAP, and relying upon any of these 
tools may result in undertreatment or overtreatment.
The limited accuracy of clinical signs and tests for VAP 
has important implications. Suspected respiratory infec-
tions, including VAP, are the biggest drivers of antimicro-
bial use in the ICU [57]. Qualitative analyses, however, 
suggest much of this utilization is unnecessary [7]. Our 
results indicate that clinicians should not initiate antibi-
otics solely on the basis of these independent signs. We 
suggest instead tailoring the urgency of antibiotics to 
severity of illness. In patients with suspected VAP and 
hemodynamic instability or severe hypoxemia, antibiot-
ics should be started expeditiously regardless of clinical 
Table 4 Summary estimates of the performance of physical examination, chest radiography, laboratory values, and CPIS 
for the diagnosis of ventilator-associated pneumonia, relative to reference standard of bronchoalveolar lavage











hood ratio  
(95% CI)
Negative likeli-






Purulent secretions 6 (557) 87.9 (68.3–96.1) 38.8 (20.4–61) 4.61 (2.66–7.99) 1.44 (1.15–1.8) 0.31 (0.17–0.58) Low
Infiltrate on chest 
radiography
7 (663) 85.2 (52.9–96.7) 18.0 (4.7–49.7) 1.26 (0.76–2.09) 1.04 (0.95–1.13) 0.82 (0.53–1.28) Low
CPIS > 6 5 (397) 75.4 (38.5–93.7) 68.3 (42.9–86.1) 6.59 (0.71–61.33) 2.38 (0.92–6.13) 0.36 (0.09–1.41) Low
certainty. If patients are more stable, however, then more 
conservative approaches should be considered. Com-
puted tomography, if available, may improve accuracy 
compared to plain chest radiography although this has 
not been sufficiently studied [58, 59]. Clinicians might 
also consider treating alternative causes of respiratory 
instability (e.g., diuresis, suctioning of mucous plugs) 
before starting antimicrobials in hemodynamically stable 
patients that can tolerate some delay in antibiotic initia-
tion [60–62]. This approach has the potential to reduce 
antimicrobial utilization but requires further investiga-
tion to confirm safety. Notably, many RCTs have used 
VAP rates as primary outcomes [63]. Our study suggests 
this is an unreliable outcome. More concrete outcomes 
such as mortality, duration of mechanical ventilation, and 
antimicrobial utilization may be more appropriate out-
comes in such trials [63].
The difficulties inherent to VAP diagnosis informed 
the Centers for Disease Control and Prevention (CDC) 
decision to move from VAP surveillance to ventilator-
associated event (VAE) surveillance for the purposes of 
internal benchmarking and quality improvement [64]. 
This approach follows from the recognition that accu-
rately diagnosing VAP using clinical signs is incredibly 
challenging, a sentiment that is supported by the results 
of this review. Instead, VAE surveillance focuses on 
detecting nosocomial deterioration in respiratory func-
tion from any cause, since this can be objectively defined 
through examining the trajectory of patients’ ventilator 
settings. This approach emphasizes the importance of 
preventing both infectious and non-infectious complica-
tions of mechanical ventilation. However, the VAE defini-
tions are designed to inform surveillance, not real-time 
clinical care.
This review was performed using a comprehensive 
search with clear inclusion and exclusion criteria, exam-
ining various clinical indicators for VAP as compared to 
two different reference standards, and included unpub-
lished data provided by study authors. We assessed risk 
of bias for individual studies and used GRADE method-
ology to assess and contextualize our findings based on 
our overall certainty in effect estimates. This review also 
has limitations. First, we evaluated clinical signs indepen-
dently. In practice, providers typically use combinations 
of signs and tests to arrive at a diagnosis. Unfortunately, 
not all combinations were amenable to meta-analysis, 
though we did evaluate the accuracy of CPIS and sum-
marize some combinations of signs evaluated in individ-
ual studies. Second, since we performed a meta-analysis 
using the published literature, there was a lack of avail-
able details on the included patients, which precluded 
our ability to perform subgroup analyses to further iden-
tify sources of heterogeneity. In particular, the accuracy 
of clinical indicators may be influenced by prior exposure 
to antibiotics. Unfortunately, the included studies did 
not always indicate whether patients had been treated 
with antimicrobials prior to sampling, thus precluding 
a sensitivity analysis restricted to patients without prior 
exposure to antimicrobials. Third, our pooled estimates 
were mostly of low certainty, due to imprecision and 
inconsistency. This suggests the need for high-quality 
studies addressing this important topic. Fourth, there is 
likely clinical heterogeneity across studies, particularly 
with relation to subjective indicators, such as purulent 
sputum and chest radiography, which may vary between 
raters. Fifth, not all tests evaluated by histopathology as 
reference standard were also amenable to testing by BAL 
as reference standard. Finally, our study may suffer from 
spectrum bias. In particular, the reference standard of 
histopathology was largely applied to deceased patients 
and therefore may reflect test performance in patients 
with more severe disease. Our findings were consistent, 
however, when using quantitative BAL cultures as the 
reference standard.
Conclusion
This systematic review and meta-analyses found that 
classically used clinical indicators, including fever, puru-
lent secretions, leukocytosis, chest radiography, cul-
tures from 3 sampling techniques (ETA, PSB, BAL), and 
CPIS had poor specificity for diagnosis of VAP. Reliance 
upon the presence of any of these indicators may result 
in misdiagnosis and possibly unnecessary antimicrobial 
utilization. These findings highlight the uncertainty of 
diagnosing VAP and underscore the need for better tools 
to help clinicians know when to start and stop empiric 
antibiotics for possible VAP.
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